This podcast activity will discuss the practical application of data and frequently asked questions from the independent satellite symposium, Potential Benefits of Incretins Beyond Glycemic Control in T2D, presented at EASD on September 19, 2022.
Speakers
Juan Pablo Frias, MD
Stefano Del Prato, MD
Professor of Endocrinology
Chief - Section of Diabetes and Metabolic Diseases
Dept of Clinical and Experimental Medicine
University of Pisa
Pisa, Italy
Stefano Del Prato is Professor of Endocrinology and Metabolism at the School of Medicine, University of Pisa and Chief of the Section of Diabetes, University Hospital of Pisa, Italy. He graduated from the University of Padova, Italy and undertook postgraduate specialization in Endocrinology and Internal Medicine. He has been Associate Professor of Medicine at the University of Texas, San Antonio, TX, USA. Professor Del Prato’s main research interests have always been the physiopathology and therapy of type 2 diabetes and insulin resistance. He is a member of many societies and associations including the European Association for the Study of Diabetes (EASD) and the American Diabetes Association. He acts as referee for numerous journals and has served on the Editorial Boards of major scientific journals in the field of diabetes and metabolism. Professor Del Prato is past Vice-President of the EASD, past Chairman of the European Foundation for the Study of Diabetes (EFSD), past President and Honorary President of the Italian Society of Diabetology, and the current President of the European Association for the Study of Diabetes. He also served as Chairman of the Scientific Committee of the World Diabetes Congress in Dubai, UAE, in 2011. He has published over 500 articles in peer-reviewed international journals and has been awarded several honors including the Prize of the Italian Society of Diabetology for outstanding scientific activity, the Honorary Professorship at the Universidad Peruana Cayetano Heredya in Lima and the title of Commander of the Order of the Italian Republic.
Accreditation and Disclosure Information
TARGET AUDIENCE
This CE activity is intended for endocrinologists, diabetologists, and endocrinology fellows who provide care for individuals with T2D.
EDUCATIONAL OBJECTIVES
After completing this CE activity, participants should be better able to:
- Evaluate the role of the first dual GIP/GLP-1 receptor agonist in treating T2D
- Initiate the dual agonist safely in appropriate patients
AGENDA
- Brief introduction to dual agonism and the first-in class agent
- Tirzepatide's potential role in therapy for T2D
- Highlights and practical tips from the US label, including safety and tolerability; FDA fast track designation for obesity
- Differences in the EU label compared with the one in the US
ACCREDITATION, SUPPORT and CREDIT
In support of improving patient care, Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Medical Learning Institute, Inc. designates this enduring material for a maximum of 0.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is supported by an educational grant by Lilly.
DISCLOSURE & CONFLICT OF INTEREST POLICY
Medical Learning Institute, Inc. is committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, we require faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to policy. These disclosures will be provided to learners prior to the start of the CE activity.
FACULTY DISCLOSURES
Planner/Presenter
Juan Pablo Frias, MD, FACE
Medical Director and Principal Investigator
Velocity Clinical Research
Los Angeles, CA
Juan Pablo Frias, MD, FACE, has a financial interest/relationship or affiliation in the form of:
Research Grant from Akero, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, 89bio, Eli Lilly, Intercept, Ionis, Janssen, Madrigal, Metacrine, Merck, NorthSea Therapeutics, Novartis, Novo Nordisk, Oramed, Pfizer, Poxel and Sanofi.
Advisory Board/Consultant for Akero, Altimmune, Axcella Health, Becton Dickinson, Boehringer Ingelheim, Carmot Therapeutics, Echosens, 89bio, Eli Lilly, Gilead, Intercept, Metacrine, Merck, Novo Nordisk, Pfizer, and Sanofi.
Speakers’ Bureau with Eli Lilly and Sanofi.
Planner/Presenter
Stefano Del Prato, MD
Professor of Endocrinology
Chief - Section of Diabetes and Metabolic Diseases
Dept of Clinical and Experimental Medicine
University of Pisa
Pisa, Italy
Professor Del Prato has a financial interest/relationship or affiliation in the form of:
Research Grant from AstraZeneca and Boehringer Ingelheim.
Advisory Board/Consultant for Abbott, Applied Therapeutics, AstraZeneca, Boehringer Ingelheim, Eli Lilly and Co, Hengrui, Merck Sharp & Dohme, Novo Nordisk, Sandoz, Sanofi, and Vertex.
Speakers’ Bureau with AstraZeneca, Boehringer Ingelheim, Eli Lilly and Co, Merck & Co, Novartis Pharmaceuticals, Novo Nordisk, and Sanofi.
All of the relevant financial relationships of individuals for this activity have been mitigated.
PLANNING COMMITTEE AND CONTENT/PEER REVIEWERS
The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
METHOD OF PARTICIPATION
There are no fees for this activity. To claim credit, participants must listen to the episode in its entirety, click the link in the show notes and complete the post-test and evaluation. A passing score of 70% or higher is needed to obtain credit. Once requirements are completed, the certificate will be emailed to you.
For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.
If you have questions regarding your certificate, please contact Mary Vu via email at mvu@mlieducation.org.
ABOUT THIS ACTIVITY
Medical Learning Institute, Inc. is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of this activity is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of Medical Learning Institute, Inc.
The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of Medical Learning Institute, Inc. or any of its partners, providers, and/or supporters.
Copyright © 2022 Medical Learning Institute, Inc. All Rights Reserved.